Sk Biopharmaceuticals Co Stock Current Valuation
| 326030 Stock | 102,100 1,500 1.45% |
Valuation analysis of Sk Biopharmaceuticals helps investors to measure Sk Biopharmaceutica's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Sk Biopharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of Sk Biopharmaceuticals is based on 3 months time horizon. Increasing Sk Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sk Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of 326030 Stock. However, Sk Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 102100.0 | Real 89355.0 | Hype 102100.0 | Naive 96387.58 |
The real value of 326030 Stock, also known as its intrinsic value, is the underlying worth of Sk Biopharmaceuticals Company, which is reflected in its stock price. It is based on Sk Biopharmaceutica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sk Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sk Biopharmaceuticals Co helps investors to forecast how 326030 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sk Biopharmaceutica more accurately as focusing exclusively on Sk Biopharmaceutica's fundamentals will not take into account other important factors: Sk Biopharmaceuticals Co Company Current Valuation Analysis
Sk Biopharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sk Biopharmaceutica Current Valuation | 5.87 T |
Most of Sk Biopharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sk Biopharmaceuticals Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sk Biopharmaceuticals Co has a Current Valuation of 5.87 T. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Republic of Korea stocks is significantly lower than that of the firm.
326030 Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sk Biopharmaceutica's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sk Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Sk Biopharmaceutica by comparing valuation metrics of similar companies.Sk Biopharmaceutica is currently under evaluation in current valuation category among its peers.
326030 Fundamentals
| Return On Equity | -0.12 | |||
| Return On Asset | 0.0475 | |||
| Profit Margin | (0.12) % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 5.87 T | |||
| Shares Outstanding | 78.31 M | |||
| Shares Owned By Insiders | 64.28 % | |||
| Shares Owned By Institutions | 5.26 % | |||
| Price To Book | 15.89 X | |||
| Price To Sales | 13.94 X | |||
| Revenue | 418.64 B | |||
| Gross Profit | 396.31 B | |||
| EBITDA | 83.87 B | |||
| Net Income | 64.85 B | |||
| Cash Flow From Operations | (92.87 B) | |||
| Earnings Per Share | (117.74) X | |||
| Target Price | 96154.0 | |||
| Number Of Employees | 10 | |||
| Beta | 1.11 | |||
| Market Capitalization | 5.32 T | |||
| Total Asset | 643.65 B | |||
| Net Asset | 643.65 B |
About Sk Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sk Biopharmaceuticals Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sk Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sk Biopharmaceuticals Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Sk Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sk Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sk Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with 326030 Stock
Moving against 326030 Stock
| 0.58 | 011200 | HMM Co | PairCorr |
| 0.57 | 032640 | LG Uplus | PairCorr |
| 0.53 | 035420 | Naver | PairCorr |
| 0.38 | 003535 | Hanwha InvestmentSecuri | PairCorr |
| 0.37 | 039240 | Gyeongnam Steel | PairCorr |
The ability to find closely correlated positions to Sk Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sk Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sk Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sk Biopharmaceuticals Co to buy it.
The correlation of Sk Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sk Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sk Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sk Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in 326030 Stock
Sk Biopharmaceutica financial ratios help investors to determine whether 326030 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 326030 with respect to the benefits of owning Sk Biopharmaceutica security.